Autism Spectrum Disorder CRISPR Cell Models for Drug Discovery

Autism spectrum disorder (ASD) affects approximately 1 in 100 children globally, according to the World Health Organization (WHO, 2023). The prevalence has increased over the past two decades, partly due to improved diagnostic criteria and awareness. ASD is characterized by persistent deficits in social communication and interaction, along with restricted, repetitive patterns of behavior, interests, or activities. The condition imposes a significant lifelong burden on individuals, families, and healthcare systems. While no curative treatment exists, early behavioral interventions can improve outcomes. The National Cancer Institute (NCI) does not track ASD, but the National Institute of Mental Health (NIMH) reports that ASD is one of the most heritable neurodevelopmental disorders, with an estimated heritability of 40-80%.

ASD is an ideal model for mechanistic studies due to its strong genetic component and the availability of large-scale genomic datasets (e.g., SFARI Gene, Autism Sequencing Consortium). The disorder encompasses a wide phenotypic spectrum, allowing researchers to investigate genotype-phenotype correlations. Key open questions include the convergence of rare and common genetic variants on shared biological pathways (e.g., synaptic function, chromatin remodeling), the role of environmental factors in gene regulation, and the development of targeted therapies for specific genetic subtypes. Gene-edited cell models, particularly those derived from induced pluripotent stem cells (iPSCs), enable the study of ASD-associated mutations in relevant human neuronal cell types.

Several biological pathways are consistently implicated in ASD pathogenesis:

• • Synaptic Signaling and Plasticity: Genes encoding postsynaptic scaffolding proteins (e.g., SHANK3, NLGN3, NRXN1) are frequently mutated. Disruption of glutamatergic and GABAergic signaling leads to an imbalance in excitation/inhibition (E/I) ratio.
• • Chromatin Remodeling and Gene Regulation: Mutations in CHD8, ARID1B, and other chromatin modifiers alter global gene expression patterns during neurodevelopment.
• • mTOR Signaling and Protein Synthesis: Dysregulation of the mTOR pathway (e.g., TSC1/TSC2, PTEN mutations) leads to abnormal synaptic protein synthesis and dendritic spine morphology.
• • Wnt/β-Catenin Signaling: Disruption of Wnt signaling affects neural progenitor proliferation and differentiation.

Data from SFARI Gene, ClinVar, and published exome sequencing studies (e.g., Satterstrom et al., 2020, Cell).

Key signaling networks disrupted in ASD include:

• • mTOR Signaling: Hyperactivation leads to increased translation of synaptic proteins, altered dendritic spine density, and impaired long-term depression (LTD). Key nodes: TSC1, TSC2, PTEN, RHEB, mTORC1.
• • MAPK/ERK Pathway: Mutations in MAPK pathway genes (e.g., BRAF, MAP2K1) are associated with syndromic ASD (e.g., Noonan syndrome). Altered ERK signaling affects neuronal differentiation and synaptic plasticity.
• • Wnt/β-Catenin Pathway: Disruption of Wnt signaling (e.g., CTNNB1 mutations) impairs neural progenitor proliferation and cortical lamination.
• • Synaptic Adhesion and Scaffolding: Neurexins (NRXN1-3) and neuroligins (NLGN1-4) mediate trans-synaptic adhesion. Mutations disrupt synapse formation and function.

Organoids offer advantages over 2D cultures by recapitulating cell-cell interactions, cortical layering, and network activity. However, they lack vascularization and mature microglia.

• • Genetically Engineered Mouse Models (GEMMs):
• • Shank3 knockout mice: exhibit social deficits, repetitive behaviors, and altered synaptic transmission.
• • Chd8 heterozygous mice: show macrocephaly, altered gene expression, and behavioral abnormalities.
• • Tsc1/Tsc2 conditional knockouts: model tuberous sclerosis complex with ASD features.
• • Induced Models:
• • Valproic acid (VPA) exposure in utero: induces ASD-like behaviors in rodents.
• • Maternal immune activation (MIA) models: poly(I:C) injection during pregnancy.
• • Non-human Primates:
• • SHANK3 mutant macaques: recapitulate social deficits and repetitive behaviors, offering higher translational relevance.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise ASD-associated mutations. For example, SHANK3 knockout iPSC lines allow researchers to study the impact of loss of function on synaptic function and neuronal network activity. Similarly, CHD8 heterozygous knockout lines model the haploinsufficiency seen in patients. These isogenic lines, available from commercial sources, are sequence-verified and free of off-target effects, providing a controlled background for mechanistic studies. Reporter lines (e.g., GFP-tagged SHANK3) enable live-cell imaging of protein localization. Gene-edited models accelerate research by eliminating the need for transient transfection or RNAi, which can introduce variability.

Knockout and knock-in lines are used to validate the functional impact of ASD-associated genes. For example, SHANK3 knockout iPSC-derived neurons show reduced dendritic spine density and impaired synaptic transmission, confirming the gene's role in synaptic scaffolding. CRISPR screens in iPSC-derived neurons can identify genetic modifiers of ASD phenotypes, such as genes that rescue synaptic deficits in SHANK3 mutant cells.

Isogenic pairs (e.g., wild-type vs. SHANK3 knockout) are used in high-throughput drug screens to identify compounds that restore synaptic function. For instance, screening libraries of FDA-approved drugs in SHANK3 mutant neurons identified insulin-like growth factor 1 (IGF-1) as a potential therapeutic. Resistance modeling is less common in ASD, but gene-edited cells can be used to study how mutations alter neuronal response to drugs.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, selectively kill or rescue ASD mutant neurons. For example, screening in CHD8 heterozygous cells may reveal vulnerabilities that could be targeted therapeutically. Additionally, gene-edited cells are used to identify secreted biomarkers (e.g., proteins, metabolites) that correlate with mutation status.